Requiring an amyloid-β1-42 biomarker may improve the efficiency of a study, and simulations may help in planning studies by Hendrix, Suzanne B
Simulation study
Th   e simulation study reported by Schneider and colleagues 
is a valuable contribution to the ﬁ   eld of Alzheimer’s 
disease. Th  e study was conducted under a detailed 
protocol and clearly lays out the assumptions that were 
made and the criteria that were used for each set of 
simulations [1]. Th  e article makes the point that some 
situations are complicated enough that standard power 
calculations do not capture the whole picture, because 
they require simplifying assumptions that may not hold. 
In these cases, power calculations may more accurately 
reﬂ  ect reality when based on simulations that do not rely 
as much on distributional assumptions.
In this study, one critical assumption is the basis of the 
main conclusion. Table 1 presents the results taken from 
Schneider and colleagues’ study, including the mean and 
standard deviation (SD) for each group for the Alzheimer 
Disease Assessment Scale – cognitive subscale (ADAS-cog). 
Th  e  diﬀ  er  ence between group means divided by the SD is 
called a standardised diﬀ  erence (or Cohen’s D value [2]) 
and allows estimation of power based on a t test. If you 
take the placebo group mean and subtract the treatment 
group mean and then divide that diﬀ   erence by the 
placebo SD, using numbers that are all shown in the table, 
you obtain the eﬀ  ect size shown in the third column, 
within the rounding error (25%, 35% and 45%). Th  is 
exercise illustrates that the eﬀ   ect size used in this 
simulation study increases and decreases proportionally 
to the standardised diﬀ  erence, which is tied mathe  mati-
cally to the power. In other words, although the sensi-
tivity of the ADAS-cog to decline over time is increased 
with the biomarker selection methods, the treatment 
diﬀ  erence was decreased in order to maintain the same 
standardised diﬀ  erence.
Although this same type of approach seems to have 
been taken for the Clinical Dementia Rating scale sum of 
boxes (CDR-sb), calculating the observed eﬀ  ect  size 
(Cohen’s D value) by taking the diﬀ  erence between group 
means divided by the SD does not correspond to the 
planned eﬀ  ect size shown in Schneider and colleagues’ 
Table 3 [1]. Th  e rows with a planned eﬀ  ect size of 25% 
have calculated values ranging from 21 to 22%, the rows 
with a planned eﬀ  ect size of 35% have calculated values 
ranging from 27 to 30%, and the rows with a planned 
eﬀ  ect size of 45% have calculated values ranging from 35 
to 39% (data not shown). It is unclear why the simulations 
consistently provide outcomes with lower eﬀ  ect  sizes 
than those planned, particularly when the ADAS-cog 
observed eﬀ  ect sizes are not biased.
Defi  ning eff  ect size
Th   ere are several diﬀ  erent ways to deﬁ  ne eﬀ  ect size [3,4]. 
Because the estimated power is often compared between 
diﬀ  erent scenarios assuming an equal eﬀ  ect size, it is 
important to know which eﬀ  ect size is assumed to be 
equal, and what impact that assumption is expected to 
have on the estimated power. Th  e means and SDs 
referred to here are the mean and SD of the change from 
baseline for each treatment group.
Abstract
A recent article by Schneider and colleagues has 
generated a lot of interest in simulation studies as a 
way to improve study design. The study also illustrates 
the foremost principal in simulation studies, which is 
that the results of a simulation are an embodiment 
of the assumptions that went into it. This simulation 
study assumes that the eff  ect size is proportional to 
the mean to standard deviation ratio of the Alzheimer 
Disease Assessment Scale – cognitive subscale in the 
population being studied. Under this assumption, 
selecting a subgroup for a clinical trial based on 
biomarkers will not aff  ect the effi   ciency of the study, 
despite achieving the desired increase in the mean to 
standard deviation ratio.
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one that is unstandardised (the absolute diﬀ  erence); and 
three that are standardised values, calculated through 
dividing by some type of scaling factor (Cohen’s D value 
using the baseline SD, Cohen’s D value using the change 
from baseline SD, and the percentage of placebo decline 
that uses the placebo mean change from baseline).
Absolute diff  erence
Th  e absolute diﬀ   erence between treatment groups is 
calculated by simply subtracting the two treatment group 
means (usually the mean changes from baseline):
Diﬀ  erence = active mean – placebo mean
Th   is observed treatment diﬀ  erence is often reported in 
addition to some type of standardised eﬀ  ect size. Th  is 
diﬀ  erence is nonstandardised so it is diﬃ   cult to compare 
between diﬀ  erent instruments, because a 2-point diﬀ  er-
ence on the ADAS-cog is not comparable with a 2-point 
diﬀ  erence on the CDR-sb. Th  e absolute diﬀ  erence on a 
single scale is also diﬃ   cult to compare between studies if 
the studies include diﬀ   erent patient populations. For 
instance, a 2-point diﬀ  erence on the ADAS-cog may be 
more meaningful in a mild patient population than in a 
Table 1. Summary statistics and power from Schneider and colleagues with absolute eff  ect size (column J), percentage 
placebo eff  ect (column K) and sensitivity (column L) in additional columns
A B C  D  E F G H I  J  K  L
             Absolute  Percentage  Sensitivity
   Eff  ect size         Power,   treatment  placebo  (signal to
n per  Dropout  (J / H =   Selection  TRT  PBO  TRT  PBO  mixed  eff  ect  eff  ect  noise ratio) 
group  (%)  K x L)  method  mean  mean  SD  SD  model  (F – E)  (J / F)  (F / H)
100 20  0.35 aMCI 0.88 2.86 5.92 5.62 0.56  1.98  0.69  0.51
100 20  0.35 Ab  1.66 3.71 6.18 5.85 0.58  2.05  0.55  0.63
100 20  0.35 t-tau/Ab  1.58 3.66 6.27 5.92 0.57  2.08  0.57  0.62
100 20  0.45 aMCI 0.33 2.85 6.03 5.61 0.71  2.52  0.88  0.51
100 20  0.45 Ab  1.04 3.73 6.25 5.88 0.76  2.69  0.72  0.63
100 20  0.45 t-tau/Ab  0.99 3.65 6.41 5.94 0.73  2.66  0.73  0.61
200 20  0.25 aMCI 0.85 2.84 5.93 5.62 0.54  1.99  0.70  0.51
200 20  0.25 Ab  1.66 3.72 6.22 5.88 0.56  2.06  0.55  0.63
200 20  0.25 t-tau/Ab  1.55 3.67 6.27 5.96 0.61  2.12  0.58  0.62
200 20  0.35 aMCI 0.32 2.85 6.08 5.65 0.78  2.53  0.89  0.50
200 20  0.35 Ab  1.05 3.71 6.28 5.86 0.83  2.66  0.72  0.63
200 20 0.35  t-tau/Ab  0.96  3.64 6.4 5.95  0.85  2.68  0.74  0.61
200 40  0.35 aMCI 0.89 2.85 5.97 5.65  0.7  1.96  0.69  0.50
200 40  0.35 Ab  1.65 3.68 6.18 5.86 0.71  2.03  0.55  0.63
200 40 0.35  t-tau/Ab  1.57  3.65 6.3 5.95  0.73  2.08  0.57  0.61
200 40  0.45 aMCI 0.32 2.87  6.1  5.65 0.86  2.55  0.89  0.51
200 40  0.45 Ab  1.06  3.7  6.34 5.87 0.88  2.64  0.71  0.63
200 40  0.45 t-tau/Ab  0.93 3.68 6.36 5.99  0.9  2.75  0.75  0.61
400 20  0.25 aMCI 1.45 2.86 5.92 5.63 0.81  1.41  0.49  0.51
400 20  0.25 Ab  2.23  3.7  6.15 5.88 0.84  1.47  0.40  0.63
400 20  0.25 t-tau/Ab  2.17 3.68 6.23 5.98 0.87  1.51  0.41  0.62
400 40  0.25 aMCI 0.86 2.85  6  5.66 0.71  1.99  0.70  0.50
400 40  0.25 Ab  1.67  3.7  6.27 5.89 0.77  2.03  0.55  0.63
400 40  0.25 t-tau/Ab  1.54 3.68 6.32  6  0.76  2.14  0.58  0.61
400 40  0.35 aMCI 1.46 2.86 5.92 5.63 0.93  1.4  0.49  0.51
400 40  0.35 Ab  2.25 3.73 6.14 5.88 0.94  1.48  0.40  0.63
400 40  0.35 t-tau/Ab  2.16 3.67 6.23  6  0.95  1.51  0.41  0.61
Adapted with permission from Table 2 of Schneider and colleagues [1]. TRT, treatment; PBO, placebo; SD, standard deviation; aMCI, amnestic mild cognitive 
impairment; Ab, requires low Ab1-42 biomarker for enrollment; t-tau, requires high total tau to Ab1-42 ratio for enrollment.
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treatment eﬀ   ect is often reported in addition to the 
absolute treatment diﬀ  erence.
Cohen’s D value using the baseline standard 
deviation
One way to standardise the eﬀ  ect size is to divide the 
observed treatment diﬀ  erence by the baseline SD. Th  is 
procedure is common and appropriate when the baseline 
scores represent some type of normal or healthy state 
from which patients may deteriorate, and then to which 
they may possibly return. Th   is value is the number of SDs 
of diﬀ   erence between the two groups relative to the 
baseline population:
Cohen’s D value using baseline SD = 
diﬀ  erence / baseline SD
In the case of Alzheimer’s disease, mild cognitive 
impair  ment or prodromal Alzheimer’s disease, the base-
line population represents an already deteriorated patient 
population so standardising based on this non-healthy 
population can therefore lead to unusual eﬀ  ect sizes. For 
instance, a homogeneous group of patients – that is, a 
population with very similar severity at baseline – may 
have a SD that is one-half that of a less homogeneous 
population with the same baseline mean. If the same 
absolute treat  ment diﬀ  erence is observed in these two 
populations, then the ﬁ   rst population would have a 
Cohen’s  D value that is twice as large as the second 
population due solely to the diﬀ   erences in baseline 
variability.
Cohen’s D value using change from baseline 
standard deviation (z-score eff  ect size or 
standardised diff  erence)
If the absolute treatment diﬀ  erence is divided by the SD 
of the change from baseline, then this eﬀ  ect size also 
represents the number of SDs of diﬀ  erence between the 
two groups relative to the changes from baseline that 
were observed. Th   is is a type of z-score calculation and is 
often referred to as a standardised diﬀ  erence. Th   is is the 
eﬀ  ect size that was used by Schneider and colleagues [1]:
Cohen’s D value eﬀ  ect size (standardised diﬀ  erence) = 
D = diﬀ  erence / placebo SD
Although the placebo SD is shown in the equation, this 
calculation sometimes uses the pooled SD across treat-
ment groups.
Th   is type of eﬀ  ect size calculation is less susceptible to 
population diﬀ  erences at baseline, but it is still suscep-
tible to diﬀ  erences in the homogeneity of the change over 
time. So if a group is more homogeneous at baseline, it is 
also likely that the changes from baseline will be more 
homogeneous, making comparison between the groups 
complicated.
Th   e other issue that factors into this calculation is the 
sensitivity of the instrument. If an instrument is used that 
has substantial variability in the change from baseline 
over time, then the Cohen’s D values will be lower than 
with an instrument with less variability. Although one 
could argue that an eﬀ  ect on a more variable instrument 
should be penalised because of the variability, it means 
that a 35% eﬀ  ect, for instance, on a variable instrument 
could be quite a lot larger than a 35% eﬀ  ect on a less 
variable instrument. Th   ere is a direct relationship 
between this standardised diﬀ  erence (D), the sample size 
and power for a two-sample t test:
Power = K x n x D2
where K is a constant that depends on α (the type 1 error 
rate, traditionally selected to be 0.05), and n is the sample 
size per group.
Percentage placebo eff  ect
Because Alzheimer’s disease, including mild cognitive 
impairment and prodromal Alzheimer’s disease, is a 
degenerative disease, a natural scaling factor is the 
placebo rate. Dividing the absolute diﬀ   erence by the 
placebo mean change from baseline results in an eﬀ  ect 
size that represents the percentage reduction in the 
placebo decline – an eﬀ   ect size >100% indicates an 
improvement over baseline:
Percentage placebo eﬀ  ect (% reduction in decline) = 
diﬀ  erence / placebo mean
Th  is  eﬀ  ect size has the advantage that it is standardised 
to time rather than to the variability of a group of 
patients. A 30% eﬀ  ect size, for instance, can therefore be 
interpreted as a reduction of 30% in the rate of the 
placebo group. Th  is  eﬀ  ect size is easily comparable across 
diﬀ  erent instruments in the same disease state because 
the sensitivity of the instrument does not aﬀ  ect the eﬀ  ect 
size. Th  is  eﬀ  ect size is also at least somewhat comparable 
between patient groups in diﬀ  erent disease states, since 
any ﬂ   oor or ceiling eﬀ   ects that may impact the 
instrument sensitivity may similarly aﬀ  ect the diﬀ  erence, 
thus not impacting the eﬀ  ect size.
An additional metric, referred to as the signal to noise 
ratio, measures the sensitivity of a particular instrument 
in a speciﬁ  c population of patients and is useful when 
using the percentage placebo eﬀ  ect:
Sensitivity (signal to noise ratio) = 
placebo mean / placebo SD
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population, and also allows estimation of ceiling and 
ﬂ  oor eﬀ  ects. Th  e signal to noise ratio multiplied by the 
percentage placebo eﬀ  ect is equal to the Cohen’s D value 
eﬀ   ect size using the change from baseline SD. Th  is 
relationship allows us to make a set of power curves 
based on the sensitivity of an instrument which can then 
be used to compare the power between diﬀ  erent percen-
tage placebo eﬀ  ects.
Discussion
Th   e three farthest right columns in Table 1 show that as 
the sensitivity increases, the percentage placebo eﬀ  ect 
size decreases. Consider the example shown in the ﬁ  rst 
three rows of Table 1, with n = 100 per group and a 
dropout rate of 20%. Th  e sensitivity of the ADAS-cog 
increases from 0.51 for the amnestic mild cognitive 
impair  ment (aMCI) group to 0.62 or 0.63 with the bio-
marker selected groups. If the percentage placebo eﬀ  ect 
of 0.69 that is shown for the aMCI group is also used for 
the two biomarker selected groups, we can estimate the 
power using Figures 1 and 2. For the aMCI group, the 
power would be approximately 0.60 (using Figure 1, eﬀ  ect 
size = 0.70; PASS 2005 [5] used for all power calculations). 
For the biomarker selected groups, the power is approxi-
mately 0.75 (using Figure 2, eﬀ  ect size = 0.70). Also using 
Figure 2, a sample size of approxi  mately 70 per group can 
achieve power of 0.60, com  parable with the power 
achieved with a sample size of 100 in the aMCI group.
Th  ere are critical diﬀ  erences in the approaches that 
have been used to discuss power and eﬀ  ect size in clinical 
trials. Below are three assumptions that correspond to 
assuming equal eﬀ  ects using three diﬀ  erent methods of 
reporting treatment eﬀ  ects.
Th  e ﬁ  rst method is the absolute diﬀ  erence. Assuming 
that the absolute treatment diﬀ  erence (point diﬀ  erence) 
is the same across diﬀ  erent trial scenarios implies that a 
treatment can give X points beneﬁ  t no matter how much 
the placebo group declines, how sensitive the instrument, 
or how hetero  geneous the population being studied. Th  is 
approach can  not reasonably be used to compare power 
between two diﬀ  erent instruments such as the ADAS-
cog and CDR-sb, since the same point diﬀ  erences on 
these two instruments would not be comparable.
Th  e second reporting method is the standardised 
diﬀ  erence or Cohen’s D value using the placebo standard 
deviation (used in Schneider and colleagues’ article [1]). 
Assuming that the standardised diﬀ  erence is the same 
across trial scenarios implies that a treatment gives the 
same percen  tage beneﬁ  t relative to the SD of the change 
from baseline of the instrument. If diﬀ  erent instruments 
used to measure a disease are similarly sensitive to 
decline over time, then this type of comparison may be 
valid. Using this method, however, an increase in 
measurement error, such as that introduced with careless 
instrument admin  is  tration, would be associated with an 
increase in the expected eﬃ   cacy of the treatment under 
consideration, suﬃ     cient to counteract the decrease in 
power due to increased variability.
Th  e ﬁ   nal method is the percentage placebo eﬀ  ect. 
Assuming that the percentage diﬀ   erence relative to 
placebo is the same across trial scenarios implies that a 
treatment gives the same percentage beneﬁ  t relative to 
the decline of the placebo group. Th  is approach could 
only be considered for a disease with an increasing 
outcome or a degenerative disease such as Alzheimer’s 
disease. In Alzheimer’s disease, use of the method assumes 
that the treatment is expected to reduce the decline by 
the same percentage across diﬀ  erent trial scenarios. Th  is 
assumption may be justiﬁ   ed when studying the same 
patient population with diﬀ  erent instruments; it may not 
be reasonable when comparing diﬀ  erent disease stages, 
however, since a treatment may not have the same 
percentage beneﬁ  t in these diﬀ  erent patient populations. 
Th  is is the basis of the argument for earlier treatment. 
Treatments may be able to aﬀ  ect the disease more in the 
earlier stages. It is not clear whether this would be related 
to the position in the disease or to the slower decline rate 
that may be expected earlier in the disease (which, inci-
den  tally, may be due to a ceiling eﬀ  ect of an instrument). 
When selecting a population based on biomarkers in 
order to increase the decline rate seen over the study 
period, it is not clear whether the same percentage eﬀ  ect 
would be expected in this subgroup, or whether the 
percentage eﬀ  ect might actually go down due to the more 
rapid progression of this subgroup. Th  is method does 
have the advantage of not depending on the sensitivity of 
the instrument being used.
Figure 3 shows the diﬀ  erence between a percentage 
placebo eﬀ  ect and a standardised diﬀ  erence. Figure 3a 
shows a 50% eﬀ  ect as a percentage of the placebo decline 
of 4 points (2-point eﬀ   ect). Figure 3b shows a 50% 
standardised diﬀ  erence eﬀ  ect when the SD is 6 points 
(3-point eﬀ  ect). Using the same 50% eﬀ  ect but a scenario 
with a smaller placebo decline (3-point decline instead of 
4-point decline), a 1.5-point diﬀ  erence is obtained for the 
placebo decline eﬀ  ect (Figure 3c) and a 3-point diﬀ  erence 
for the standardised eﬀ  ect (Figure 3d) since the SD was 
kept at 6 points. Th  ese data illustrate the diﬀ  erence 
between a percentage eﬀ   ect relative to placebo and a 
standardised diﬀ  erence that is relative to the SD.
Although observing similar power when comparing 
biomarker selected groups and the aMCI group as a 
whole is a direct result of using the same standardised 
diﬀ  erence, column J in Table 1 shows that the absolute 
diﬀ  erence is also quite similar between the biomarker 
selected groups and the aMCI group, and is actually 
larger for the aMCI group. Th   is indicates the conclusion 
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biomarker selection may be valid if a treatment has a 
similar absolute diﬀ  erence in all three groups. In fact, the 
power diﬀ  erences would be even less than were shown 
since the absolute treatment diﬀ   erence shown for the 
aMCI group is slightly smaller than for the two biomarker 
selected groups.
Th  e question therefore comes down to the issue of 
whether selecting a faster declining patient group, which 
generally increases the mean to SD ratio of an instrument 
(by increasing both the mean and the SD, but increasing 
the mean more than the SD), will also result in an 
increase in eﬀ   ect proportional to the increase in the 
mean placebo decline. Previous power comparisons have 
assumed that it will. Schneider and colleagues assume 
that this selection would not but that the eﬀ  ect will stay 
proportionally the same relative to the SD, resulting in no 
eﬀ  ect on power [1]. Another way of assuming that this 
selection will not result in an increase in eﬀ  ect 
proportional to the increase in the mean placebo decline 
would be to assume a constant absolute treatment eﬀ  ect. 
Th  is assumption also results in very similar power 
between aMCI and biomarker selected groups.
Conclusions
Simulation studies are an appropriate way to explore the 
impact of diﬀ  erent study design decisions in order to 
improve the study design. Th   e results of a simulation are 
an embodiment of the assumptions that went into it. Th  is 
simulation study assumes that the eﬀ   ect size is pro-
portional to the mean to SD ratio of the ADAS-cog in the 
population being studied. Because this type of eﬀ  ect size 
increases proportionally to the mean to SD ratio, 
increasing the mean to SD ratio cannot aﬀ  ect the power. 
Th  e small diﬀ  erences in power that were observed by 
Schneider and colleagues between the three selection 
Figure 1. Power estimation for the amnestic mild cognitive impairment group. Power for a mean to standard deviation ratio of 0.50 (20% dropout).
Figure 2. Power estimation for the biomarker selected group. Power for a mean to standard deviation ratio of 0.60 (20% dropout).
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the measurement error compo  nent of the treatment 
response. In addition, the CDR-sb is not able to show 
increased power despite its improved sensitivity to 
decline (signal to noise ratio), because the eﬀ  ect size, as 
deﬁ  ned, increases proportionally to the signal to noise 
ratio – although there are some concerns about the 
observed eﬀ  ect sizes calculated from Table 3 in Schneider 
and colleagues’ paper [1]. Assuming a constant absolute 
treat ment  eﬀ   ect also results in very similar estimated 
power between the aMCI and biomarker selected groups.
Assuming a constant percentage placebo eﬀ  ect size does 
show diﬀ   erences in the power for the selected patient 
subgroups. Th  is assumption also shows improved power 
of the CDR-sb over the ADAS-cog, speciﬁ  cally due to the 
improvement in sensitivity or signal to noise ratio.
Separating the evaluation of an instrument in its ability 
to measure the decline in Alzheimer’s disease over time 
(sensitivity) from the ability of a treatment to aﬀ  ect the 
decline over time (percentage placebo eﬀ  ect size) clariﬁ  es 
the discussion of power, eﬃ   ciency and sample size.
Th  ere is no way to know whether selecting a faster 
declining patient group, which generally increases the 
mean to SD ratio of an instrument, will also result in an 
increase in eﬀ   ect proportional to the increase in the 
mean placebo decline. Previous power comparisons have 
assumed that it will. Both the approach described in 
Schneider and colleagues’ article and an approach using a 
constant absolute treatment eﬀ   ect assume that this 
selection would not increase the eﬀ  ect, resulting in very 
similar power between the aMCI and biomarker selected 
groups.
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